Spots Global Cancer Trial Database for A Trial to Evaluate Safety and Tolerability of INCSHR01210 in Cancer Patients
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: A Trial to Evaluate Safety and Tolerability of INCSHR01210 in Cancer Patients
Official Title: An Open-Label, Multicenter, Nonrandomized, Dose-Escalation and Tumor-Expansion Phase 1 Study to Evaluate the Safety and Tolerability of INCSHR01210 (Formerly SHR-1210) in Subjects With Advanced Solid Tumors
Study ID: NCT02492789
Conditions
Interventions
Study Description
Brief Summary: This is an open-label, multicenter, non-randomized, dose escalation and tumor-expansion phase I trial to evaluate safety and tolerability of INCSHR01210 in patients with advanced solid tumors. The trial will enroll subjects with advanced solid tumor who have failed current standard anti-tumor therapies.
Detailed Description:
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
Austin Hospital/Olivia Newton-John Cancer Research Institute, Heidelberg, Victoria, Australia
Blacktown Hospital, Blacktown, , Australia
Chris O'Brien Life House, Camperdown, , Australia
Nucleus Network, Melbourne, , Australia
Linear Clinical Research Limited, Nedlands, , Australia
Contact Details
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
